A prospective, randomized, double-blind, multicenter trial to evaluate the therapeutic efficacy and safety of palonosetron in the treatment of postoperative nausea and vomiting over a 72-h period

Hahm, Tae Soo; Hwang, Jung Won; Oh, Eun Jung; Kim, Duk Kyung; Choi, Won Joon; Kim, Yun Hong; Ryu, Jung Hee; Yoo, Byung Hoon; Yon, Jun Heum

doi:10.1007/s00540-014-1884-9

Cited by 4 publications

(2 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Palonosetron administration resulted in a higher rate of PONV resolution when compared to placebo. 92 In patients who received ondansetron prophylaxis, administration of palonosetron resulted in complete response in 25% of the patients, this was not significantly different from administration of additional ondansetron dose as rescue. 93 Hence, we do not recommend redosing of 5-HT 3 receptor antagonists if a previous dose was administered within 6 hours.…”

Section: Novel Rescue Treatmentmentioning

confidence: 88%

Prevention and Treatment of Postoperative Nausea and Vomiting (PONV): A Review of Current Recommendations and Emerging Therapies

Jin¹,

Gan²,

Bergese³

2020

TCRM

View full text Add to dashboard Cite

Postoperative nausea and vomiting is one of the most frequent adverse events after surgery and anesthesia. It is distressing for the patient and can lead to other postoperative complications. Management of PONV involves a framework of risk assessment, multimodal risk reduction, and prophylactic measures, as well as prompt rescue treatment. There has been a significant paradigm shift in the approach towards PONV prevention. There have also been several emerging therapeutic options for PONV prophylaxis and treatment. In this review, we will discuss the up-to-date PONV management guidelines and highlight novel therapeutic options which have emerged in the last few years.

show abstract

Section: Novel Rescue Treatmentmentioning

confidence: 88%

Prevention and Treatment of Postoperative Nausea and Vomiting (PONV): A Review of Current Recommendations and Emerging Therapies

Jin¹,

Gan²,

Bergese³

2020

TCRM

View full text Add to dashboard Cite

show abstract

“…Risk of bias was intermediate. 24 conducted a study multicenter of 152 patients who developed PONV after undergoing laparoscopic surgery under inhalation anesthesia with N 2 O. After 2 hours, 14% of patients given palonosetron required additional antiemetics, compared to 27% in the placebo group (P = .049).…”

Section: B1mentioning

confidence: 99%

Rescue Treatment of Postoperative Nausea and Vomiting: A Systematic Review of Current Clinical Evidence

Gan

Jin

Meyer

2022

Anesthesia &Amp; Analgesia

View full text Add to dashboard Cite

Although prophylactic antiemetics are commonly used perioperatively, an estimated 30% of surgical patients still suffer from postoperative nausea and vomiting (PONV). Very few prospective trials have studied rescue treatment of PONV after failure of prophylaxis, providing limited evidence to support clinical management. In patients who have failed PONV prophylaxis, administering a rescue antiemetic from the same drug class has been reported to be ineffective. For many antiemetics currently used in PONV rescue, significant uncertainty remains around the effective dose range, speed of onset, duration of effect, safety, and overall risk-benefit ratio. As prompt, effective PONV rescue after failure of prophylaxis is important to optimize postoperative recovery and resource utilization, we conduct this systematic review to summarize the current evidence available on the topic.

show abstract

Use of palonosetron and ondansetron in the prophylaxis of postoperative nausea and vomiting in women 60 years of age or older undergoing laparoscopic cholecystectomy

Braga

Figueiredo

Barrucand

et al. 2019

European Journal of Anaesthesiology

View full text Add to dashboard Cite

A prospective, randomized, double-blind, multicenter trial to evaluate the therapeutic efficacy and safety of palonosetron in the treatment of postoperative nausea and vomiting over a 72-h period

Abstract: A single 0.075 mg IV dose of palonosetron effectively increased the CR rates at 24 and 72 h in these moderate-risk patients with established PONV.

Cited by 4 publications

References 34 publications

Prevention and Treatment of Postoperative Nausea and Vomiting (PONV): A Review of Current Recommendations and Emerging Therapies

Prevention and Treatment of Postoperative Nausea and Vomiting (PONV): A Review of Current Recommendations and Emerging Therapies

Rescue Treatment of Postoperative Nausea and Vomiting: A Systematic Review of Current Clinical Evidence

Use of palonosetron and ondansetron in the prophylaxis of postoperative nausea and vomiting in women 60 years of age or older undergoing laparoscopic cholecystectomy

Contact Info

Product

Resources

About